Monograph
R06AX13 - Loratadine |
Propably not porphyrinogenic |
PNP |
Rationale
Metabolised by CYP 3A4. Inducer of CYP 3A4. Two references consider it safe. Clinical experience (Swedish) seems to point to non-porphyrinogenicity.
Chemical description
Antihistamine without sedative effect used (10 mg/d p.o.) in allergic rhinitis/conjunctivitis and in histamine mediatid pruritus and urticaria. The same general structure as cyproheptadine (PSP). Metabolized by CYP 3A4. Main metabolite is decarboxyethoxyloratidine with an elimination half time of 19 hours. South African list: use with care French list: authorized Andersson, patient reports (N=13): tolerated. Thunell: occasionally observed to be tolerated. C.Andersson, patient reports: tolerated (n=4)
IPNet drug reports
Uneventful use reported in 28 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
